<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03709654</url>
  </required_header>
  <id_info>
    <org_study_id>NB01-P1BMA</org_study_id>
    <nct_id>NCT03709654</nct_id>
  </id_info>
  <brief_title>A Study of the Safety, Engraftment, and Action of Multi-Dosed NB01 in Adults With Moderate Acne</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase 1B Study of the Safety, Short-Term Engraftment and Action of NB01 in Adults With Moderate Acne</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Naked Biome, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Naked Biome, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acne vulgaris is a disease caused my multiple factors including overgrowth of bacteria,&#xD;
      clogged pores, excessive sebum production and hormonal changes. Recent literature from the&#xD;
      Human Microbiome Project has shown there are bacterial strains specific to healthy and acne&#xD;
      disease states (Fitz-Gibbon et al, 2013, Johnson et al, 2016, McDowell et al, 2012, Tomida et&#xD;
      al, 2013)&#xD;
&#xD;
      From this data, the investigators hypothesize that by eliminating disease-associated&#xD;
      bacterial strains and replacing them with health-associated strains, recurrences or flares of&#xD;
      acne may be improved, mitigated, and prevented. Instead of current approaches which focus on&#xD;
      eliminating all bacteria from the skin, the investigators aim to deliver healthy bacteria to&#xD;
      restore the skin to a healthy state via this replacement therapy.&#xD;
&#xD;
      The investigators aim to test this in a Phase Ib multiple application study evaluating the&#xD;
      safety, tolerability, and clinical impact that a multiple applications of NB01 have on adult&#xD;
      subjects with moderate acne.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase 1B Study of the Safety,&#xD;
      Short-Term Engraftment and Action of NB01 in Adults With Moderate Acne&#xD;
&#xD;
      Acne vulgaris is a multifactorial disease caused by overgrowth of Propionibacterium acnes (P.&#xD;
      acnes), impaction of hair follicles, excessive sebum production and hormonal dysregulation.&#xD;
      Recent literature from the Human Microbiome Project has shown there are unique microbial&#xD;
      signatures specific to healthy and acne disease states.&#xD;
&#xD;
      From this data, the investigators hypothesize that by eliminating resident disease-associated&#xD;
      bacterial strains and replacing them with health-associated strains, recurrences/fares of&#xD;
      acne may be improved, mitigated, and prevented. Instead of current approaches which focus on&#xD;
      eliminating all bacteria from the skin, the investigators aim to deliver healthy bacteria&#xD;
      (NB01) to restore the skin to a healthy state via this replacement therapy.&#xD;
&#xD;
      The investigators aim to test this in a Phase 1B multiple application study evaluating the&#xD;
      safety, tolerability, and clinical impact that a multiple, daily, applications of NB01 has on&#xD;
      adult subjects with moderate acne. Investigators will be profiling the change in microbiome&#xD;
      over the course of therapy to determine if exogenously delivered bacteria can populate the&#xD;
      skin (engraftment) and cause a shift in the microbiome safely and subsequently impact acne&#xD;
      biomarkers that may correlate with clinical disease.&#xD;
&#xD;
      The investigators intend for this therapy to eventually be used in acne subjects with ages&#xD;
      ranging from 13-40, and all disease severities as either monotherapy for mild to&#xD;
      mild/moderate acne and as an adjuvant therapy for moderate to severe acne at all body sites,&#xD;
      with special attention to facial involvement.&#xD;
&#xD;
      This approach is standard to acne therapy whereby mild disease will be treated with a&#xD;
      monotherapy (i.e., topical Benzoyl peroxide [BPO]) and moderate/severe disease will be&#xD;
      treated with various combinatory regimens (topical antibiotics, BPO, topical retinoids, oral&#xD;
      antibiotics).&#xD;
&#xD;
      Primary Objectives:&#xD;
&#xD;
      1. To determine the safety and tolerability of a multiple application of topical P. acnes&#xD;
      microbiome transplant (&quot;NB01&quot;).&#xD;
&#xD;
      Exploratory Objectives:&#xD;
&#xD;
        1. To define engraftment duration of NB01.&#xD;
&#xD;
        2. To evaluate preliminary clinical efficacy using Acne Lesion Counts (total, inflammatory,&#xD;
           and non-inflammatory), Investigator Global Assessment (IGA), and subjective improvement&#xD;
           of acne based on subject reported outcomes (Acne QoL Questionnaire).&#xD;
&#xD;
        3. To evaluate treatment effects, based on sebum production in a subpopulation from sites&#xD;
           02 and 03.&#xD;
&#xD;
      Approximately 36 total male and female adult subjects combined with moderate, non-cyclical&#xD;
      acne will be enrolled into the trial. Approximately twenty four (24) subjects will be&#xD;
      randomly assigned treatment and twelve (12) subjects will be randomly assigned to vehicle&#xD;
      control.&#xD;
&#xD;
      This is a multiple topical application study of live bacteria for the study of acne in adult&#xD;
      subjects. Following a 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill&#xD;
      resident facial bacterial, 11 weeks of daily topical application of NB01 will be evaluated.&#xD;
&#xD;
      Subject participation in the trial will approximately 12 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Actual">September 30, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Double Blind Vehicle Controlled Trial, dual arm with 2:1 treatment to vehicle assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Changes in Local Skin Reactions</measure>
    <time_frame>Day 0 through day 80</time_frame>
    <description>Local Skin Reactions (LSRs) including Erythema, edema, erosion/ulceration, scaling/dryness, and scabbing/crusting scored at Baseline (day of first application) and Week 12 (end of treatment) and reported for each visit as: Absent, Mild, Moderate, or Severe.&#xD;
The number of participants (and %) with no change or improvement from Baseline to week 12 visit are reported.&#xD;
The number of participants (and %) whose score worsened from Baseline to week 12 visit are reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Successful Follicular Engraftment of NB01</measure>
    <time_frame>12 weeks</time_frame>
    <description>Follicular engraftment sampling used Biore® Strips at Screening and day 80 (several days after end of treatment).&#xD;
The number of subjects with &quot;success&quot; at EOT where &quot;success&quot; is defined as a Follicular Biore® sample with &quot;yes&quot; outcome based on recovery of live NB01at day 80.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute Change in Genotype Markers: Skin Surface Engraftment &quot;Success&quot;</measure>
    <time_frame>Day 0 through day 80</time_frame>
    <description>Skin surface engraftment &quot;success&quot; endpoint is deﬁned by a change in genotype (TaqMan) markers compared to Screening; value is percentage of bacterial population containing health-associated genotype. Result is absolute change from screening value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute Change From Screening in Acne Lesion Counts</measure>
    <time_frame>Day 0 through day 80</time_frame>
    <description>Reporting absolute change in counts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change From Screening in Acne Lesion Counts</measure>
    <time_frame>Day 0 through day 80</time_frame>
    <description>Efficacy endpoint: Percent change from Screening lesion counts at Day 80 (end of treatment)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Achieving &quot;Success&quot; on Investigator Global Assessment (IGA)</measure>
    <time_frame>Day 0 through day 80</time_frame>
    <description>The investigator assessed the participant's inflammatory lesions on the face using the Investigator Global Assessment (IGA) 5-point scale.&#xD;
The scale ranges from 0 (best): clear, no evidence of papules or pustules to 4 (worst): severe, inflammatory lesions are more apparent, many papules/pustules.&#xD;
The outcome is the number of subjects in each treatment group achieving &quot;success&quot; at Week 12; &quot;success&quot; defined as an IGA score of &quot;clear (score=0)&quot; or &quot;almost clear (score=1)&quot; and at least a two-point reduction in IGA compared to Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Acne QoL Questionnaire Score</measure>
    <time_frame>Day 0 through day 80</time_frame>
    <description>At each visit, subjects were asked to complete the Acne Quality of Life [QoL] Questionnaire to assess subjective improvement of acne with 7 response choices ranging from extremely to not at all. The total score ranges from 19 to 114; higher scores reflect improved QoL.&#xD;
Outcome measure is absolute change in Acne QoL (Total Score) from Baseline to Day 80.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute Change From Screening in Acne Lesion Counts: Outlier Censored</measure>
    <time_frame>Day 0 through day 80</time_frame>
    <description>After reviewing the data, one Treatment Arm subject was found to be an extreme outlier and was censored from this ad-hoc analysis.&#xD;
Reporting absolute change in counts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change From Screening in Acne Lesion Counts: Outlier Censored</measure>
    <time_frame>Day 0 through day 80</time_frame>
    <description>Efficacy endpoint: Percent change from Screening lesion counts at Day 80 (end of treatment)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Follicular Engraftment</measure>
    <time_frame>12 weeks</time_frame>
    <description>Follicular communities were genotyped for health-associated loci at both Screening and 12-week visits. The percent increase of Cas5 in multiple communities from each subject is reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Sebum Production.</measure>
    <time_frame>Day 0 through day 80</time_frame>
    <description>Exploratory Endpoint: Absolute change from Baseline to week 12 in sebum production measured at the mid-glabellar region of the forehead using a Sebumeter.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of NB01 probiotic applied topically.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of vehicle applied topically.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NB01</intervention_name>
    <description>5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of NB01</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle Control</intervention_name>
    <description>5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of vehicle control</description>
    <arm_group_label>Vehicle Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject has provided written informed consent.&#xD;
&#xD;
          2. Subject is male or non-pregnant female, 18-40 years of age, inclusive at Screening.&#xD;
&#xD;
          3. Subject has moderate facial acne vulgaris&#xD;
&#xD;
          4. Female subject with non-cyclical acne.&#xD;
&#xD;
          5. Women of childbearing potential (WOCBP) willing to use adequate contraception during&#xD;
             study participation&#xD;
&#xD;
          6. Male subjects willing to use an acceptable method of contraception during study&#xD;
             participation.&#xD;
&#xD;
          7. Subject has the ability to personally apply benzoyl peroxide (BPO) and study drug, as&#xD;
             per protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has active bacterial, viral, or fungal skin infections.&#xD;
&#xD;
          2. Subject has active nodulocystic acne or acne conglobate, acne fulminans, or other&#xD;
             forms of acne (e.g., acne mechanica).&#xD;
&#xD;
          3. Subject is currently participating in an investigational drug, device, or biologic&#xD;
             study or has used an investigational drug, biologic or device treatment within 30 days&#xD;
             prior to first application of the study drug.&#xD;
&#xD;
          4. Subjects with prosthetic heart valves, pacemakers, intravascular catheters, or other&#xD;
             foreign or prosthetic devices/implantable devices/hardware.&#xD;
&#xD;
          5. Subject has a history of chronic human immunodeficiency virus (HIV), hepatitis C virus&#xD;
             (HCV), or hepatitis B virus (HBV) infections.&#xD;
&#xD;
          6. Subject has a history of malignancy (with the exception of non-melanoma skin cancer).&#xD;
&#xD;
          7. Subject is immunosuppressed (such as resulting from transplantation, immunosuppressive&#xD;
             therapy, active HIV infection/acquired immune deficiency syndrome [AIDS],&#xD;
             neutropenia).&#xD;
&#xD;
          8. Subject had a major surgical procedure, open biopsy, or significant traumatic injury&#xD;
             within 14 days of initiating study drug (unless the wound has healed), or anticipation&#xD;
             of the need for major surgery during the study.&#xD;
&#xD;
          9. Subjects with close contacts (e.g., spouses, children, or members in the same&#xD;
             household) that have severe skin barrier defects or are immunocompromised.&#xD;
&#xD;
         10. Female subject is pregnant or lactating or is planning to become pregnant and/or&#xD;
             breast feed within the duration of study participation.&#xD;
&#xD;
        Other entry criteria not listed above will be reviewed of each prospective subject by the&#xD;
        study staff to confirm eligibility&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emma Taylor, MD</last_name>
    <role>Study Director</role>
    <affiliation>Naked Biome</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>03</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>01</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>02</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.dermnetnz.org/topics/acne-vulgaris</url>
    <description>DermNet New Zealand. Acne vulgaris: Acne Grading</description>
  </link>
  <link>
    <url>http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071292</url>
    <description>[FDA] Guidance for Industry: Acne Vulgaris: Developing Drugs for Treatment. Draft: September 2005</description>
  </link>
  <link>
    <url>https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/General/UCM292704.pdf</url>
    <description>Early Clinical Trials with Live Biotherapeutic FDA Guidance for Industry: Products: Chemistry, Manufacturing, and Control Information</description>
  </link>
  <link>
    <url>https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/General/UCM292704.pdf</url>
    <description>FDA Guidance for Industry CGMP for Phase 1 Investigational Drugs</description>
  </link>
  <results_reference>
    <citation>Fitz-Gibbon S, Tomida S, Chiu BH, Nguyen L, Du C, Liu M, Elashoff D, Erfe MC, Loncaric A, Kim J, Modlin RL, Miller JF, Sodergren E, Craft N, Weinstock GM, Li H. Propionibacterium acnes strain populations in the human skin microbiome associated with acne. J Invest Dermatol. 2013 Sep;133(9):2152-60. doi: 10.1038/jid.2013.21. Epub 2013 Jan 21.</citation>
    <PMID>23337890</PMID>
  </results_reference>
  <results_reference>
    <citation>Johnson T, Kang D, Barnard E, Li H. Strain-Level Differences in Porphyrin Production and Regulation in Propionibacterium acnes Elucidate Disease Associations. mSphere. 2016 Feb 10;1(1). pii: e00023-15. doi: 10.1128/mSphere.00023-15. eCollection 2016 Jan-Feb.</citation>
    <PMID>27303708</PMID>
  </results_reference>
  <results_reference>
    <citation>McDowell A, Barnard E, Nagy I, Gao A, Tomida S, Li H, Eady A, Cove J, Nord CE, Patrick S. An expanded multilocus sequence typing scheme for propionibacterium acnes: investigation of 'pathogenic', 'commensal' and antibiotic resistant strains. PLoS One. 2012;7(7):e41480. doi: 10.1371/journal.pone.0041480. Epub 2012 Jul 30.</citation>
    <PMID>22859988</PMID>
  </results_reference>
  <results_reference>
    <citation>Tomida S, Nguyen L, Chiu BH, Liu J, Sodergren E, Weinstock GM, Li H. Pan-genome and comparative genome analyses of propionibacterium acnes reveal its genomic diversity in the healthy and diseased human skin microbiome. mBio. 2013 Apr 30;4(3):e00003-13. doi: 10.1128/mBio.00003-13.</citation>
    <PMID>23631911</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 9, 2018</study_first_submitted>
  <study_first_submitted_qc>October 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <results_first_submitted>June 4, 2020</results_first_submitted>
  <results_first_submitted_qc>July 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 3, 2020</results_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acne</keyword>
  <keyword>pimple</keyword>
  <keyword>black head</keyword>
  <keyword>white head</keyword>
  <keyword>zit</keyword>
  <keyword>probiotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Initially there is no plan to share IPD. This may change later as the clinical plan develops.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 18, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT03709654/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT03709654/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Arm</title>
          <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of NB01 probiotic applied topically.&#xD;
NB01: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of NB01</description>
        </group>
        <group group_id="P2">
          <title>Vehicle Control</title>
          <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of vehicle applied topically.&#xD;
Vehicle Control: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of vehicle control</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Arm</title>
          <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of NB01 probiotic applied topically.&#xD;
NB01: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of NB01</description>
        </group>
        <group group_id="B2">
          <title>Vehicle Control</title>
          <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of vehicle applied topically.&#xD;
Vehicle Control: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of vehicle control</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.3" spread="6.19"/>
                    <measurement group_id="B2" value="24.6" spread="4.7"/>
                    <measurement group_id="B3" value="24.4" spread="5.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Investigator's Global Assessment (IGA) Score - Face</title>
          <description>The investigator assessed the participant's inflammatory lesions on the face using the IGA 5-point scale at screening visit and baseline visits.&#xD;
The scale ranges from 0 (best): clear, no evidence of papules or pustules to 4 (worst):</description>
          <units>Score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>IGA at Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" spread="0"/>
                    <measurement group_id="B2" value="3" spread="0"/>
                    <measurement group_id="B3" value="3" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGA at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" spread="0"/>
                    <measurement group_id="B2" value="3" spread="0"/>
                    <measurement group_id="B3" value="3" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Skin bacterial genotype</title>
          <description>Skin genotype is the percentage of bacterial population containing health-associated genotypes as measured with TaqMan from a skin swabbed sample.</description>
          <units>percentage of genotype</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>deoR/Panbac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.8" spread="24.2"/>
                    <measurement group_id="B2" value="26.0" spread="27.4"/>
                    <measurement group_id="B3" value="23.3" spread="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cas5/Panbac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.3" spread="12.8"/>
                    <measurement group_id="B2" value="7.8" spread="13.0"/>
                    <measurement group_id="B3" value="7.5" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Count</title>
          <units>number of lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Inflammatory lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.1" spread="7.3"/>
                    <measurement group_id="B2" value="30.5" spread="5.6"/>
                    <measurement group_id="B3" value="29.6" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Inflammatory lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.9" spread="13.5"/>
                    <measurement group_id="B2" value="37.4" spread="12.8"/>
                    <measurement group_id="B3" value="36.4" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Changes in Local Skin Reactions</title>
        <description>Local Skin Reactions (LSRs) including Erythema, edema, erosion/ulceration, scaling/dryness, and scabbing/crusting scored at Baseline (day of first application) and Week 12 (end of treatment) and reported for each visit as: Absent, Mild, Moderate, or Severe.&#xD;
The number of participants (and %) with no change or improvement from Baseline to week 12 visit are reported.&#xD;
The number of participants (and %) whose score worsened from Baseline to week 12 visit are reported.</description>
        <time_frame>Day 0 through day 80</time_frame>
        <population>The Safety population included all randomized subjects who received and applied study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of NB01 probiotic applied topically.&#xD;
NB01: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of NB01</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Control</title>
            <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of vehicle applied topically.&#xD;
Vehicle Control: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of vehicle control</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Changes in Local Skin Reactions</title>
          <description>Local Skin Reactions (LSRs) including Erythema, edema, erosion/ulceration, scaling/dryness, and scabbing/crusting scored at Baseline (day of first application) and Week 12 (end of treatment) and reported for each visit as: Absent, Mild, Moderate, or Severe.&#xD;
The number of participants (and %) with no change or improvement from Baseline to week 12 visit are reported.&#xD;
The number of participants (and %) whose score worsened from Baseline to week 12 visit are reported.</description>
          <population>The Safety population included all randomized subjects who received and applied study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema: No Change / Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Edema: No Change / Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Edema: Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erosion/Ulceration: No Change / Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erosion/Ulceration: Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scaling/Dryness: No Change / Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scaling/Dryness: Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scabbing/Crusting: No Change / Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scabbing/Crusting: Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching: No Change / Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching: Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: No Change / Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Successful Follicular Engraftment of NB01</title>
        <description>Follicular engraftment sampling used Biore® Strips at Screening and day 80 (several days after end of treatment).&#xD;
The number of subjects with &quot;success&quot; at EOT where &quot;success&quot; is defined as a Follicular Biore® sample with &quot;yes&quot; outcome based on recovery of live NB01at day 80.</description>
        <time_frame>12 weeks</time_frame>
        <population>The modified intent-to-treat (mITT) population included all randomized subjects who were dispensed the study drug and had at least 1 post-baseline assessment. Subjects were included in the treatment group to which they were randomized, regardless of the treatment received.&#xD;
All randomized subjects (N=36) were included in the mITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of NB01 probiotic applied topically.&#xD;
NB01: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of NB01</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Control</title>
            <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of vehicle applied topically.&#xD;
Vehicle Control: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of vehicle control</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Successful Follicular Engraftment of NB01</title>
          <description>Follicular engraftment sampling used Biore® Strips at Screening and day 80 (several days after end of treatment).&#xD;
The number of subjects with &quot;success&quot; at EOT where &quot;success&quot; is defined as a Follicular Biore® sample with &quot;yes&quot; outcome based on recovery of live NB01at day 80.</description>
          <population>The modified intent-to-treat (mITT) population included all randomized subjects who were dispensed the study drug and had at least 1 post-baseline assessment. Subjects were included in the treatment group to which they were randomized, regardless of the treatment received.&#xD;
All randomized subjects (N=36) were included in the mITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change in Genotype Markers: Skin Surface Engraftment &quot;Success&quot;</title>
        <description>Skin surface engraftment &quot;success&quot; endpoint is deﬁned by a change in genotype (TaqMan) markers compared to Screening; value is percentage of bacterial population containing health-associated genotype. Result is absolute change from screening value.</description>
        <time_frame>Day 0 through day 80</time_frame>
        <population>modified intent-to-treat (mITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of NB01 probiotic applied topically.&#xD;
NB01: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of NB01</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Control</title>
            <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of vehicle applied topically.&#xD;
Vehicle Control: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of vehicle control</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Genotype Markers: Skin Surface Engraftment &quot;Success&quot;</title>
          <description>Skin surface engraftment &quot;success&quot; endpoint is deﬁned by a change in genotype (TaqMan) markers compared to Screening; value is percentage of bacterial population containing health-associated genotype. Result is absolute change from screening value.</description>
          <population>modified intent-to-treat (mITT)</population>
          <units>percentage of bacterial population</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Genotype 1 (deoR), 2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="20.32"/>
                    <measurement group_id="O2" value="2.5" spread="14.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype 1 (deoR), 7 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="17.63"/>
                    <measurement group_id="O2" value="2.9" spread="16.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype 1 (deoR), 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="25.27"/>
                    <measurement group_id="O2" value="14.9" spread="36.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype 2 (Cas 5), 2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="8.16"/>
                    <measurement group_id="O2" value="4.8" spread="12.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype 2 (Cas 5), 7 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="17.84"/>
                    <measurement group_id="O2" value="3.9" spread="10.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype 2 (Cas 5), 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="10.32"/>
                    <measurement group_id="O2" value="19.6" spread="38.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change From Screening in Acne Lesion Counts</title>
        <description>Reporting absolute change in counts.</description>
        <time_frame>Day 0 through day 80</time_frame>
        <population>modified intent-to-treat (mITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of NB01 probiotic applied topically.&#xD;
NB01: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of NB01</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Control</title>
            <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of vehicle applied topically.&#xD;
Vehicle Control: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of vehicle control</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Screening in Acne Lesion Counts</title>
          <description>Reporting absolute change in counts.</description>
          <population>modified intent-to-treat (mITT) population</population>
          <units>lesion count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Inflammatory Lesion Count: week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="4.77"/>
                    <measurement group_id="O2" value="-4.7" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inflammatory Lesion Count: week 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.4" spread="6.64"/>
                    <measurement group_id="O2" value="-6.7" spread="7.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inflammatory Lesion Count: week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.5" spread="7.84"/>
                    <measurement group_id="O2" value="-14.5" spread="9.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Inflammatory Lesion Count: week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="8.89"/>
                    <measurement group_id="O2" value="-3.0" spread="6.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Inflammatory Lesion Count: week 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" spread="8.58"/>
                    <measurement group_id="O2" value="-9.2" spread="8.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Inflammatory Lesion Count: week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15" spread="16.93"/>
                    <measurement group_id="O2" value="-17.6" spread="10.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Screening in Acne Lesion Counts</title>
        <description>Efficacy endpoint: Percent change from Screening lesion counts at Day 80 (end of treatment)</description>
        <time_frame>Day 0 through day 80</time_frame>
        <population>modified intent-to-treat (mITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of NB01 probiotic applied topically.&#xD;
NB01: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of NB01</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Control</title>
            <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of vehicle applied topically.&#xD;
Vehicle Control: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of vehicle control</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Screening in Acne Lesion Counts</title>
          <description>Efficacy endpoint: Percent change from Screening lesion counts at Day 80 (end of treatment)</description>
          <population>modified intent-to-treat (mITT) population</population>
          <units>percent change from Baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Inflammatory Lesion Count: week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.8" spread="18.72"/>
                    <measurement group_id="O2" value="-14.8" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inflammatory Lesion Count: week 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.9" spread="20.72"/>
                    <measurement group_id="O2" value="-20.0" spread="22.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inflammatory Lesion Count: week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.8" spread="26.29"/>
                    <measurement group_id="O2" value="-49.2" spread="27.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Inflammatory Lesion Count: week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" spread="23.99"/>
                    <measurement group_id="O2" value="-6.2" spread="16.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Inflammatory Lesion Count: week 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.0" spread="23.55"/>
                    <measurement group_id="O2" value="-21.5" spread="17.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Inflammatory Lesion Count: week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.5" spread="44.96"/>
                    <measurement group_id="O2" value="-49" spread="23.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Achieving &quot;Success&quot; on Investigator Global Assessment (IGA)</title>
        <description>The investigator assessed the participant's inflammatory lesions on the face using the Investigator Global Assessment (IGA) 5-point scale.&#xD;
The scale ranges from 0 (best): clear, no evidence of papules or pustules to 4 (worst): severe, inflammatory lesions are more apparent, many papules/pustules.&#xD;
The outcome is the number of subjects in each treatment group achieving &quot;success&quot; at Week 12; &quot;success&quot; defined as an IGA score of &quot;clear (score=0)&quot; or &quot;almost clear (score=1)&quot; and at least a two-point reduction in IGA compared to Baseline.</description>
        <time_frame>Day 0 through day 80</time_frame>
        <population>modified intent-to-treat (mITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of NB01 probiotic applied topically.&#xD;
NB01: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of NB01</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Control</title>
            <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of vehicle applied topically.&#xD;
Vehicle Control: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of vehicle control</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving &quot;Success&quot; on Investigator Global Assessment (IGA)</title>
          <description>The investigator assessed the participant's inflammatory lesions on the face using the Investigator Global Assessment (IGA) 5-point scale.&#xD;
The scale ranges from 0 (best): clear, no evidence of papules or pustules to 4 (worst): severe, inflammatory lesions are more apparent, many papules/pustules.&#xD;
The outcome is the number of subjects in each treatment group achieving &quot;success&quot; at Week 12; &quot;success&quot; defined as an IGA score of &quot;clear (score=0)&quot; or &quot;almost clear (score=1)&quot; and at least a two-point reduction in IGA compared to Baseline.</description>
          <population>modified intent-to-treat (mITT) population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Success at 2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Success at 7 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Success at 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Acne QoL Questionnaire Score</title>
        <description>At each visit, subjects were asked to complete the Acne Quality of Life [QoL] Questionnaire to assess subjective improvement of acne with 7 response choices ranging from extremely to not at all. The total score ranges from 19 to 114; higher scores reflect improved QoL.&#xD;
Outcome measure is absolute change in Acne QoL (Total Score) from Baseline to Day 80.</description>
        <time_frame>Day 0 through day 80</time_frame>
        <population>modified intent-to-treat (mITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of NB01 probiotic applied topically.&#xD;
NB01: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of NB01</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Control</title>
            <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of vehicle applied topically.&#xD;
Vehicle Control: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of vehicle control</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Acne QoL Questionnaire Score</title>
          <description>At each visit, subjects were asked to complete the Acne Quality of Life [QoL] Questionnaire to assess subjective improvement of acne with 7 response choices ranging from extremely to not at all. The total score ranges from 19 to 114; higher scores reflect improved QoL.&#xD;
Outcome measure is absolute change in Acne QoL (Total Score) from Baseline to Day 80.</description>
          <population>modified intent-to-treat (mITT) population</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" spread="16.2"/>
                    <measurement group_id="O2" value="33.2" spread="23.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change From Screening in Acne Lesion Counts: Outlier Censored</title>
        <description>After reviewing the data, one Treatment Arm subject was found to be an extreme outlier and was censored from this ad-hoc analysis.&#xD;
Reporting absolute change in counts.</description>
        <time_frame>Day 0 through day 80</time_frame>
        <population>Ad Hoc Subject 02-005 (outlier) Censored mITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of NB01 probiotic applied topically.&#xD;
NB01: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of NB01</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Control</title>
            <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of vehicle applied topically.&#xD;
Vehicle Control: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of vehicle control</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Screening in Acne Lesion Counts: Outlier Censored</title>
          <description>After reviewing the data, one Treatment Arm subject was found to be an extreme outlier and was censored from this ad-hoc analysis.&#xD;
Reporting absolute change in counts.</description>
          <population>Ad Hoc Subject 02-005 (outlier) Censored mITT Population</population>
          <units>lesion count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Inflammatory Lesion Count: week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="4.82"/>
                    <measurement group_id="O2" value="-4.7" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inflammatory Lesion Count: week 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" spread="6.81"/>
                    <measurement group_id="O2" value="-6.7" spread="7.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inflammatory Lesion Count: week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.1" spread="7.79"/>
                    <measurement group_id="O2" value="-14.5" spread="9.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Inflammatory Lesion Count: week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="2.77"/>
                    <measurement group_id="O2" value="-3.0" spread="6.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Inflammatory Lesion Count: week 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.7" spread="7.35"/>
                    <measurement group_id="O2" value="-9.2" spread="8.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Inflammatory Lesion Count: week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18" spread="10.31"/>
                    <measurement group_id="O2" value="-17.6" spread="10.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Screening in Acne Lesion Counts: Outlier Censored</title>
        <description>Efficacy endpoint: Percent change from Screening lesion counts at Day 80 (end of treatment)</description>
        <time_frame>Day 0 through day 80</time_frame>
        <population>Ad Hoc Subject 02-005 Censored mITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of NB01 probiotic applied topically.&#xD;
NB01: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of NB01</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Control</title>
            <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of vehicle applied topically.&#xD;
Vehicle Control: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of vehicle control</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Screening in Acne Lesion Counts: Outlier Censored</title>
          <description>Efficacy endpoint: Percent change from Screening lesion counts at Day 80 (end of treatment)</description>
          <population>Ad Hoc Subject 02-005 Censored mITT Population</population>
          <units>percent change from Baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Inflammatory Lesion Count: week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.2" spread="18.91"/>
                    <measurement group_id="O2" value="-14.8" spread="20.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inflammatory Lesion Count: week 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.0" spread="21.25"/>
                    <measurement group_id="O2" value="-20.0" spread="22.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inflammatory Lesion Count: week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53.0" spread="25.72"/>
                    <measurement group_id="O2" value="-49.2" spread="27.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Inflammatory Lesion Count: week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.5" spread="8.55"/>
                    <measurement group_id="O2" value="-6.2" spread="16.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Inflammatory Lesion Count: week 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.8" spread="20.18"/>
                    <measurement group_id="O2" value="-21.5" spread="17.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Inflammatory Lesion Count: week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.8" spread="26.42"/>
                    <measurement group_id="O2" value="-49.0" spread="23.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Follicular Engraftment</title>
        <description>Follicular communities were genotyped for health-associated loci at both Screening and 12-week visits. The percent increase of Cas5 in multiple communities from each subject is reported.</description>
        <time_frame>12 weeks</time_frame>
        <population>modified intent-to-treat (mITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of NB01 probiotic applied topically.&#xD;
NB01: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of NB01</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Control</title>
            <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of vehicle applied topically.&#xD;
Vehicle Control: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of vehicle control</description>
          </group>
        </group_list>
        <measure>
          <title>Follicular Engraftment</title>
          <description>Follicular communities were genotyped for health-associated loci at both Screening and 12-week visits. The percent increase of Cas5 in multiple communities from each subject is reported.</description>
          <population>modified intent-to-treat (mITT) population</population>
          <units>Percent increase Cas5</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6518.9" spread="6711.94"/>
                    <measurement group_id="O2" value="492" spread="939.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Sebum Production.</title>
        <description>Exploratory Endpoint: Absolute change from Baseline to week 12 in sebum production measured at the mid-glabellar region of the forehead using a Sebumeter.</description>
        <time_frame>Day 0 through day 80</time_frame>
        <population>modified intent-to-treat subpopulation visiting a subset of sites with a Sebumeter.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of NB01 probiotic applied topically.&#xD;
NB01: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of NB01</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Control</title>
            <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of vehicle applied topically.&#xD;
Vehicle Control: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of vehicle control</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Sebum Production.</title>
          <description>Exploratory Endpoint: Absolute change from Baseline to week 12 in sebum production measured at the mid-glabellar region of the forehead using a Sebumeter.</description>
          <population>modified intent-to-treat subpopulation visiting a subset of sites with a Sebumeter.</population>
          <units>μg/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2" spread="52.48"/>
                    <measurement group_id="O2" value="-22.9" spread="34.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment Arm</title>
          <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of NB01 probiotic applied topically.&#xD;
NB01: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of NB01</description>
        </group>
        <group group_id="E2">
          <title>Vehicle Control</title>
          <description>Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of vehicle applied topically.&#xD;
Vehicle Control: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of vehicle control</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA version 21.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site dryness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Application site irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Emma Taylor, MD CEO</name_or_title>
      <organization>Naked Biome</organization>
      <phone>626-260-1230</phone>
      <email>emma.t@nakedbiome.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

